Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMKJ485)

Drug Name
Pioglitazone Drug Info
Synonyms
111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
Therapeutic ClassHypoglycemic Agents
Cross-matching ID
PubChem CID
4829
ChEBI ID
CHEMBL595
CAS Number
CAS 111025-46-8
TTD Drug ID
D03OFF
VARIDT Drug ID
DR00518
INTEDE Drug ID
DR1295
ACDINA Drug ID
D00534

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.18 0.00e+0 44/46 (95.65%) PSMA6;PSMA3;PSMC4;...
RNA transport 2.04 0.00e+0 128/186 (68.82%) PRMT5;NDC1;EIF4A3;...
Ribosome biogenesis in eukaryotes 1.99 5.57e-3 52/108 (48.15%) NMD3;NXT1;POP7;...
Prion disease 1.97 6.26e-3 209/273 (76.56%) PPIF;CAV2;IL1A;...
Parkinson disease 1.97 5.01e-3 176/249 (70.68%) PPIF;DAXX;CALML5;...
Ribosome 1.97 4.18e-3 113/158 (71.52%) MRPS12;MRPL15;RPS5;...
Amyotrophic lateral sclerosis 1.93 3.58e-3 267/364 (73.35%) DAXX;NDC1;TUBB2A;...
DNA replication 1.79 1.36e-2 34/36 (94.44%) SSBP1;POLA2;POLE3;...
Folate biosynthesis 1.76 1.76e-2 23/26 (88.46%) AKR1B10;AKR1C3;MOCOS;...
Oocyte meiosis 1.74 2.09e-2 90/129 (69.77%) CDC20;PLK1;ANAPC1;...
Alzheimer disease 1.74 1.90e-2 279/369 (75.61%) PPIF;IDE;IL1A;...
Nucleotide excision repair 1.72 2.16e-2 40/47 (85.11%) RAD23B;MNAT1;CCNH;...
Huntington disease 1.69 2.89e-2 233/306 (76.14%) PPIF;CLTB;TUBB2A;...
Homologous recombination 1.68 2.92e-2 35/41 (85.37%) SSBP1;RAD51;RBBP8;...
Cell cycle 1.67 2.90e-2 110/124 (88.71%) CDC20;PLK1;E2F2;...
Pathways of neurodegeneration 1.65 3.60e-2 354/475 (74.53%) PPIF;DAXX;IL1A;...
Spinocerebellar ataxia 1.63 3.83e-2 128/143 (89.51%) PPIF;PSMA6;PSMA3;...
Progesterone-mediated oocyte maturation 1.63 3.62e-2 75/100 (75%) PLK1;ANAPC1;IGF1;...
IL-17 signaling pathway 1.61 4.35e-2 84/94 (89.36%) S100A7;S100A9;S100A8;...
Oxidative phosphorylation 1.60 4.68e-2 93/133 (69.92%) NDUFC1;CYC1;ATP5MC1;...
Other glycan degradation -1.84 4.10e-2 13/18 (72.22%) ENGASE;NEU1;GLB1;...
Lysosome -2.07 0.00e+0 115/128 (89.84%) LIPA;LAPTM4A;PSAP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 1.11uM - 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H